10X Genomics Inc
NASDAQ:TXG
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.14
22.68
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
10X Genomics Inc
NASDAQ:TXG
|
2.9B USD |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.3T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
240.3B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
171B USD |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
38.3B CHF |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
41.1B USD |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
278.3B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
39.6B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
83T KRW |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
29.5B USD |
Loading...
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
19.8B EUR |
Loading...
|
Market Distribution
| Min | -4 087 900% |
| 30th Percentile | -5.1% |
| Median | 6% |
| 70th Percentile | 14.8% |
| Max | 1 032 600% |
Other Profitability Ratios
10X Genomics Inc
Glance View
10X Genomics Inc. stands as a beacon of innovation in the rapidly evolving field of genomics, where the frontier of scientific discovery meets commercial enterprise. Founded in 2012, the company emerged from a vision to delve deeper into the cellular universe, offering tools that illuminate the complexities of biological systems. Nestled in the heart of Silicon Valley, the company has harnessed cutting-edge technology to develop platforms that enable scientists to observe cellular behavior with unprecedented clarity and detail. These tools are particularly vital for understanding the nuances of diseases and developing more targeted therapeutic interventions. At its core, 10X Genomics specializes in creating sophisticated single-cell and spatial analysis solutions, which allow researchers to dissect the minutiae of genetic information within individual cells—an advancement that traditional bulk sequencing techniques simply cannot achieve. This innovative approach is not just a scientific marvel but a robust business model that thrives on the burgeoning demand for advanced genomic research. 10X Genomics generates revenue through a blend of product sales and services. Its primary offerings include instruments and proprietary consumables, such as reagent kits that are fundamental to extracting actionable insights from genomic data. The company’s unique Chromium and Visium platforms are sought after by academic institutions, pharmaceutical companies, and clinical research organizations worldwide. By coupling high-margin consumables with sophisticated hardware, 10X Genomics ensures a recurring revenue stream that supports sustained growth. Meanwhile, it continues to invest heavily in research and development, ensuring its place at the cutting edge of genomic science and maintaining a competitive advantage in a space that demands relentless innovation.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for 10X Genomics Inc is -21%, which is above its 3-year median of -31.5%.
Over the last 3 years, 10X Genomics Inc’s Operating Margin has increased from -31.9% to -21%. During this period, it reached a low of -40.1% on Jun 30, 2024 and a high of -21% on Oct 30, 2025.